I agree, really doesn’t merit a seperate thread but the answer...

I agree, really doesn’t merit a seperate thread but the answer is it has absolutely no impact. Their distribution footprint is tiny compared to our US, Asia, HK and pending UK, Europe and Canada deals

- Uk : per recent announcements
- Europe: CEO has confirmed to me previously Europe is too big for just OOH Medical
- Canada: recent website find is very similar to OOH medical sone weeks ago

SKN are nice to have but hasn’t impacted the HCT SP at all since announced, that’s because all the upside is for SKN to add credibility to their product.

I think you will find the ASX questions are more related the the AFR article on funding sources than the original test results suspension, and however long it takes to resolve they will sell invisisheild anyway so it’s really net zero impact either way for HCT.

I hope it gets resolved for them quickly though and it’s a nice to have revenue stream and for holders hope it works out. But very small piece of the HCT jigsaw